TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06302231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and Exercise Approaches
Description: Intermittent fasting plus energy restriction combined with aerobic exercise performed in a fasted state.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and Exercise Approaches
Description: Intermittent fasting plus energy restriction combined with aerobic exercise performed in a fed state.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary Approach
Description: Intermittent fasting plus energy restriction without aerobic exercise training.
Study: NCT06325878

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genome-wide association study
Description: Alleles/haplotypes evidence through GWAS will be compared between patients with CIDP and control subjects without CIDP

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genome-wide association study
Description: Alleles/haplotypes evidence through GWAS will be compared between patients with CIDP and control subjects without CIDP
Study: NCT06544434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy)
Description: MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy)
Description: MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.

Intervention type: DRUG
Group type: OTHER
Intervention: Betahistine Mesylate tablet
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine Mesylate tablet
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Betahistine Mesylate tablet
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.
Study: NCT05176418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose Nicotine
Description: IV nicotine infused over different delivery rates
Study: NCT04842864

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: 23 hours fasting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: 23 hours fasting
Study: NCT06314490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nL-SCN2A-002
Description: Personalized antisense oligonucleotide
Study: NCT06138275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: subcutaneous (under the skin) injection
Study: NCT05242016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: structured individual reminiscence
Description: reminiscence therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: unstructured social interview
Description: placebo
Study: NCT06414512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMBITION trial control
Description: Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine
Description: Participants in the trial will receive 60mg/kg/day of 5-FC in 3 divided doses for 10 days. Single-dose liposomal amphotericin (10mg/kg) is preferred, if available. Amphotericin B 0.7-1.0 mg/kg/day may be used if needed.
Study: NCT05342103

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high flow oxygenation
Description: All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high flow oxygenation
Description: All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
Study: NCT04833101

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: recombinant Ad5 vectored COVID-19 vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant Ad5 vectored COVID-19 vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: recombinant Ad5 vectored COVID-19 vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant Ad5 vectored COVID-19 vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RBD-based protein subunit vaccine (ZF2001) against COVID-19
Description: This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBD-based protein subunit vaccine (ZF2001) against COVID-19
Description: This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RBD-based protein subunit vaccine (ZF2001) against COVID-19
Description: This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBD-based protein subunit vaccine (ZF2001) against COVID-19
Description: This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
Study: NCT05176418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose Nicotine
Description: IV Nicotine infused over different delivery rates
Study: NCT05742139

Intervention type: OTHER
Intervention: Non intervention
Description: Non intervention
Study: NCT04833101

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: trivalent split influenza vaccine
Description: This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: trivalent split influenza vaccine
Description: This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.
Study: NCT00057187

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contracting, Prompting and Reinforcing
Study: NCT05285254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Certified Child Life Specialist Support
Description: Provides psychosocial care to children and families confronting stressful and painful situations
Study: NCT05261503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEP
Description: The Homeostasis-Enrichment-Plasticity (HEP) intervention group will receive 45 minutes of face-to-face environmental enrichment-based intervention one day per week and online home support once a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Phsical Therapy
Description: The Traditional Physical Therapy group will receive a 45-minute intervention, two days a week for 12 weeks.
Study: NCT06110741

Intervention type: OTHER
Intervention: Blood and saliva sampling
Description: Collecting blood and saliva sample

Intervention type: OTHER
Intervention: Survey
Description: Collecting data on infectious diseases during the study period

Intervention type: OTHER
Intervention: Survey
Description: Collecting data on infectious diseases during the study period
Study: NCT06317350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS-212-E1
Description: Subjects who are randomized into this group will take GNS-212-E1 from the evening before colonoscopy to the morning of colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS-212-E2
Description: Subjects who are randomized into this group will take GNS-212-E2 from the evening before colonoscopy to the morning of colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNS-212-ER
Description: Subjects who are randomized into this group will take active control drug (PEG3350) from the evening before colonoscopy to the morning of colonoscopy.
Study: NCT04975828

Intervention type: DIAGNOSTIC_TEST
Intervention: albumin creatinine ratio -EGFR-fundus examination- coronary angiography.
Description: albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: albumin creatinine ratio -EGFR-fundus examination- coronary angiography.
Description: albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: albumin creatinine ratio -EGFR-fundus examination- coronary angiography.
Description: albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: albumin creatinine ratio -EGFR-fundus examination- coronary angiography.
Description: albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.
Study: NCT05415033

Intervention type: OTHER
Group type: OTHER
Intervention: BREAST-Q
Description: arabic version of breast questionnaire
Study: NCT05394233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed
Description: Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours, every 3 weeks, Pemetrexed, 500 mg/m2, intravenously every 3 weeks, Tislelizumab, 200 mg IV every 3 weeks
Study: NCT05833243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified diaphragmatic training
Description: Modified diaphragmatic strength training prescriptions will be given based on the result of baseline assessment. The intensity is 60% from the maximum respiratory muscle strength from baseline and weekly remeasurement. Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard diaphragmatic training
Description: standard diaphragmatic strength training prescriptions will be given as daily routine, 3 times a day.~Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist.
Study: NCT04913818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BUDPA Program
Description: The overall program includes 12 weekly 1-hour training class. Each session starts with a 10-minute warm-up period using stretching exercise and stationary mobilizing exercise for trunk and limb joints at both upper and lower bodies (e.g. shoulders, elbows, wrists, hips, knees and ankles), and followed by a session of four to six selected partnering exercise, with duration increase gradually from 20 minutes to 40minutes in four weeks' time. The Borg Rate of Perceived Exertion (Borg RPE) will be used to monitor the exercise intensity. The Research assistant will explain the Borg RPE scale to the subjects and instruct them to speed up or slow down their movements. The training session will end with a 10-minute cool down session with walking exercise and stationary trunk and limb mobilizing exercise involving joints of shoulders, elbows, wrists, hips, knees, and ankles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm (Usual care)
Description: Active Comparator: Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training
Study: NCT04788069

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wholemeal bread
Description: 180g wholemeal bread/day + fixed portion at test day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sourdough bread
Description: 180g sourdough bread/day + fixed portion at test day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bread with sourdough
Description: 180g bread with sourdough/day + fixed portion at test day
Study: NCT04173312

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine infusion
Description: Local systemic Infusion of anesthetic

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Local systemic infusion of saline
Study: NCT06312982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Enrolled patients will receive tislelizumab 3 times after initiation of radiotherapy.
Study: NCT06012864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PNL
Description: percutaneous extraction of the stones in the kidney
Study: NCT04925258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPACE Parenting Program
Description: The program involves a two-arm randomized trial of differing parenting interventions which include: a service as usual (SAU) cohort, in which parents are provided with local and online parenting and family mental health resources; An intervention group called SPACE that includes weekly parenting materials (i.e., two online \~10-minute videos, ten parent-child activities that were developed for the Building Regulation in Dual Generations (BRIDGE) Therapy program (NCT04347707 and NCT04639557) intervention group. Additionally, this group will receive weekly drop-in sessions with a facilitator-led (trained MA-level or higher psychology student or psychologist) interactive parenting group to re-enforce concepts and provide social support.
Study: NCT05428904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulation
Description: Virtual reality applications are a type of three-dimensional computer-based simulation that gives a sense of being anywhere and provides various data to the sense organs for this. However, virtual reality applications are a simulation model that creates a sense of reality for the participants and allows mutual communication with a computer-based dynamic environment.
Study: NCT04694729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: videoconference-based
Description: Exercises will be done 3 days a week for 6 weeks, with the help of a physiotherapist via video conference.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-based
Description: The exercise video will be sent to the patients and they will do it 3 days a week for 6 weeks. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
Study: NCT05164497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deliberate practice training
Description: The experimental condition consists of five weeks of deliberate practice training of non-specific psychotherapy skills organized as (1) classroom training and (2) homework. The classroom training consists of 15 hours (5 days x 3 hours) of deliberate practice training. Each day will be organized around a theme: (a) Empathy, (b) establishing the therapeutic alliance, (c) working with alliance ruptures, (d) formulation of an interpersonal focus, and (e) clinical expertise - a synthesis. The training will include theoretical introductions, students defining individual training goals, model responses of good psychotherapeutic skills, and student role-play. Regarding homework, after each of the five classes, the students will use Theravue to watch and respond to three therapy videos related to the theme of the previous class. The students have to deliver at least two new responses to each video informed by feedback from teachers and peers and a checklist describing a good response.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theoretical teaching
Description: The control condition will consist of five weeks of theoretical teaching of non-specific psychotherapy skills performed as (1) classroom teaching and (2) homework. Regarding classroom teaching, the 15 hours (5 days x 3 hours) of teaching will be organized around the same five themes as the experimental condition (see points a-d above). The class will consist of the teacher's presentation of theory and research findings, videos with master therapists defining core concepts, and group discussions of literature. Regarding homework, the participants will read literature and use a restricted version of Theravue to complete home assignments where they record their answers to three theoretical questions related to the theme of the preceding classroom teaching.
Study: NCT06155084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP518 - Dose Escalation
Description: Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP518 - Dose Escalation
Description: Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP518 -Dose Expansion
Description: Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
Study: NCT05284019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Concentrate for solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Solution for SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin-A
Description: Solution for IM Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Solution for SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Solution for SC Injection
Study: NCT04884425

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Frequency Device (Energy5)
Description: A pulsed electromagnetic frequency (PEMF) device which is recommended to be used for 30 minutes a day
Study: NCT06324071

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sham
Description: Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity
Description: Participants in the Experimental group will receive a daily dose of 125 mg of TetraSOD® in a capsule during 90 days.
Study: NCT05937009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orienteering exercise program
Description: Orienteering exercise program running for 12 weeks (30-45 minutes, 3 sessions/week). Sessions will have 4 phases: 1) Signature of attendance sheet; 2) warm-up exercises for 5 minutes; 3) Start of orienteering proofs, where the departs will occur individually, with 3 interval minutes between participants; 4) stretches session, to return to a calm state.
Study: NCT04996199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks \& 10weeks
Study: NCT04843124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote HA adjustment
Description: The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional hearing aid
Description: Traditional hearing aid
Study: NCT06516055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1B-408
Description: Medication with multiple monoamine activities
Study: NCT05822843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG206
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG206
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG206
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG206
Description: Administered via intravenous (IV) infusion
Study: NCT05407532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group with oral management
Description: The investigators provided information on oral health care plus oral exercises before meals, including salivary glands massage methods.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group with oral care
Description: The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.